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Abstract Treatment of human embryonic kidney 293 cells ex- 
pressing the rat ~/-aminobutyric acid (GABA) transporter 1 
(GATI) with the protein kinase C (PKC) activator phorbol 12- 
myristate 13-acetate (PMA) was found to decrease the velocity 
of specific [3H]GABA uptake. This downregulation varied with 
extracellular GABA concentration and was blocked by the PKC 
inbibitors 1-(5-isoquinolinylsulphonyl)-2-methylpiperazine 017)
and staurosporine. An about 50% reduction of uptake velocity by 
PMA treatment was observed at GABA concentrations >1 pM, 
whereas only a minor effect was seen at low substrate concentra- 
tions. These data indicate that GATI activity is downregulated 
by PKC activation. 
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system, Corey et al. [10] found an upregulation of GABA up- 
take caused by an increase in the maximal transport velocity 
(Vmax) upon phorbol ester treatment. This discrepancy may 
reflect differences in drug application, since the former investi- 
gators added the ester to the incubation medium, whereas 
Corey et al. injected it directly into the oocytes. Here, we used 
a mammalian cell expression system to re-analyse PKC modu- 
lation of this transporter p otein. The human embryonic kidney 
cell line 293 (HEK-293) has been widely employed to express 
brain membrane proteins [11,12], and we therefore transfected 
GAT1 cDNA into these cells for investigating the effect of 
phorbol ester. Our data show that the velocity of GABA uptake 
mediated by GAT1 is decreased upon activation of PKC. 
2. Materials and methods 
1. Introduction 
y-Aminobutyric a id (GABA) is the major inhibitory neuro- 
transmitter in the vertebrate central nervous ystem, where it 
activates a variety of GABA receptor subtypes. The actions of 
GABA released upon nerve stimulation are thought o be ter- 
minated by its rapid re-uptake via GABA transporters into 
presynaptic neurons and surrounding glial cells [1,2]. Recently, 
cDNAs encoding four different GABA transporters (GATI~; 
reviewed in [3]) have been isolated. The corresponding tran- 
scripts show distinct distribution patterns, and the respective 
proteins differ in their pharmacological characteristics. Thus, 
in addition to the known heterogeneity of GABA receptors, the 
various GATs contribute to the molecular heterogeneity of
GABAergic synapses, and modulation of their activity could 
add another level of synaptic regulation. 
Most neurotransmitter ransporters contain putative phos- 
phorylation sites [1], and some have been shown to be regulated 
via kinase systems [4-8]. In case of the major GABA trans- 
porter in mammalian brain, GAT1, the data reported sofar are 
controversial. Upon treatment of Xenopus oocytes expressing 
GAT1 with phorbol ester known to activate protein kinase C 
(PKC), Osawa and colleagues [9] observed a downregulation 
in GABA transport esulting from a decrease in substrate affin- 
ity. In contrast, when using the same heterologous expression 
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2.1. Materials 
[3H]GABA (86 Ci/mmol) was obtained from Amersham. Phorbol 
12-myristate 13-acetate (PMA), staurosporine, 1-(5-isoquinolinylsulph- 
onyl)-2-methylpiperazine (H7), amiloride, and dimethylamiloride all 
were purchased from Sigma. 
2.2. Cloning of GAT1 cDNA 
The cDNA coding for GAT1 was isolated by screening a AZAPII rat 
spinal cord library with a PCR fragment containing nucleotide posi- 
tions 46-1773 of the GAT1 sequence [13]. This resulted in the isolation 
of a full-length cDNA encompassing all nucleotides of the published 
GATl-coding sequence and 150 and 2104 bp of the 5' and 3' untrans- 
lated regions, respectively [13]. For heterologous expression, the coding 
sequence ofGAT1, including 150 bp of 5' untranslated sequence and 
165 bp of 3' untranslated sequence, was subcloned into the NotI/HpaI 
sites of the eucaryotic expression vector pCIS [14]. The resulting clone, 
termed pGAT, was used throughout this study. 
2.3. Cell transfection and [3H]GABA uptake assays 
HEK-293 cells (ATCC CRL 1573) were grown and transfected as
described elsewhere [15,16]. For uptake measurements, cells were 
plated into 24 well dishes (d = 2 cm) and transfected with 1/tg of DNA. 
36-48 h after transfection, the culture medium was replaced by 0.2 ml 
of transport buffer (TBI: 100 mM NaC1, 2 mM KCI, 1 mM CaC12, 
1 mM MgC12, 10 mM HEPES, pH 7.5) containing radioactively labelled 
substrate. After incubation for 3 min (if not indicated otherwise ) at 
room temperature, the medium was removed by suction, and the cells 
were washed twice with TB1 and then extracted with 0.4 ml of 10% 
(w/v) sodium dodecylsulfate. Radioactivity was determined byscintilla- 
tion counting using a Beckman LS60001IC scintillation counter. PMA 
treatment ofthe cultures was performed for 1 h before the determina- 
tion of [3H]GABA uptake, ifnot indicated otherwise. All data represent 
the means of quadruplicate d teminations. S.E. values (indicated by 
bars) were routinely < 10%. Protein concentrations were determined 
using the Detergent Compatible Protein Assay (BioRad), using bovine 
serum albumin as a standard. 
3. Results 
3.1. [3H]GABA uptake by recombinant GAT1 
Functional expression of GAT1 was achieved by transient 
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Fig. 3. Effects of PKC inhibitors on PMA-modulated [3H]GABA up- 
take. Cells were incubated in the presence or absence of H7 (100 pM) 
or staurosporine (0.3,uM) for 1 h. Then 100 nM PMA, or 4~-PDD, was 
added for another hour as indicated, and the specific uptake of 
[3H]GABA was determined at 40 pM GABA containing 10 nM 
[3H]GABA as tracer. 
ble decrease of [3H]GABA uptake (Fig. 3). The PKC inhibitors 
staurosporine (0.3 pM) and H7 (100 pM) both caused a com- 
plete block of the PMA-induced ownregulation f GAT1 ac- 
tivity (Fig. 3). At the indicated concentrations, both kinase 
inhibitors did not affect GATl-mediated GABA uptake when 
applied alone (Fig. 3). 
3.3. Saturation analysis of [3H]GABA uptake 
To examine the mechanism of GAT1 downregulation by 
PMA, we determined [3H]GABA uptake at different substrate 
concentrations before and after phorbol ester treatment. An 
Eadie-Hofstee analysis [17] showed that pretreatment with 
PMA reduced the Vmax from 275 + 59 pmol/well/min to 
118 + 0.01 pmol/well/min without significantly affecting its Km 
value (control, 15 + 5.4¢tM; PMA-treated, 9.4 + 2.7/.tM; n = 2; 
Fig. 5). Determination f the protein contents in control and 
treated wells confirmed that PMA treatment did not change the 
total protein content of the cultures (data not shown). 
3.4. Reduction of FH]GABA uptake by PMA varies with 
external GABA concentration 
When measuring the PMA-induced reduction of [3H]GABA 
uptake at different external GABA concentrations, high 
GABA concentrations always gave a larger reduction of 
GABA uptake by PMA than observed at lower substrate con- 
centrations. To corroborate this finding, we determined the 
extent of PMA-induced inhibition over a wide range of external 
GABA concentrations. Fig. 5A shows that at GABA concen- 
trations < 500 nM, inhibition was about 25% and largely inde- 
pendent of the substrate concentration. At GABA concentra- 
tions > 500 nM, however, inhibition decreased to --50% inhibi- 
tion at 50/,tM, i.e. a concentration at which GATl-mediated 
transport is saturated (cf. Fig. 4). 
3.5. PMA does not affect the Na+/I-I + exchange system 
Treatment of some cell types with the phorbol ester 12-0- 
tetradecanoylphorbol-13-acetate (TPA) is known to activate an 
amiloride-sensitive Na+/H ÷ exchange system, which results in 
alkalization and an increase in intracellular sodium concentra- 
tion [18,19]. This TPA-induced Na+/H + exchange system is in- 
101 
hibited by amiloride and dimethylamiloride, a more potent 
derivatives [18,19]. To investigate he possible involvement of
this exchange system in the reduction of [3H]GABA uptake seen 
upon PMA treatment, we analysed GATl-mediated uptake in 
the presence of saturating concentrations of amiloride and di- 
methylamiloride, r spectively. At both 10 and 100 ~tM, neither 
of these drugs affected the PMA-mediated decrease in 
[3H]GABA uptake seen in GATl-transfected cells (data not 
shown). Therefore, the reduction of GATl-mediated 
[3H]GABA uptake seen upon PMA treatment is not due to 
PKC effects on the Na+/H + exchange system. 
4.  D iscuss ion  
In the present study we show that activation of PKC causes 
a downregulation f recombinant rat GAT 1 expressed inHEK- 
293 cells. Treatment of the GAT1 expressing cells with low 
doses of the phorbol ester PMA resulted in a reduction of the 
velocity of [3H]GABA uptake without affecting the substrate 
affinity of the transporter. Preincubation with the PKC inhib- 
itors staurosporine and H7 caused a complete block of the 
PMA-induced ownregulation f GAT1 activity, whereas the 
inactive phorbol ester 4c~-PDD had no effect. Thus, the de- 
crease of specific GATl-mediated [3H]GABA uptake induced 
by PMA is due to PKC activation. However, wether this regu- 
lation results from a direct phosphorylation f the transporter 
molecule or involves indirect mechanisms, e.g. activation of 
another signaling system that regulates GAT1 activity, is not 
clear. Also, we do not know whether the actual number of 
GAT1 molecules on the cell surface is altered upon PMA treat- 
ment, since high-affinity ligands or specific antibodies are not 
available for this transporter. Our observation that the extent 
of PMA-induced reduction of GAT1 activity correlates with 
extracellular substrate concentration, is consistent with the idea 
that not the number of GAT1 molecules on the cell surface, but 
their transport properties are changed upon PKC activation. 
Interestingly, a maximal reduction of [3H]GABA uptake by 
PMA was observed at extracellular GABA concentrations be- 
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Fig. 4. Inhibition of [3H]GABA uptake by PMA. Saturation character- 
istics were determined by the addition of unlabelled GABA to 10 nM 
[3H]GABA using both PMA-treated (e) and untreated cells (©). Trans- 
port kinetic values were calculated using the Eadie-Hofstee transfor- 
mation. K m and Vm,x values obtained in this particular experiment were 
18.7 ,uM and 317 pmol/mirdwell (control cells) and 11.3/tM and 118 
pmol/min/well (PMA-treated cells). The inset shows the respective sat- 
uration curves. 
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Fig. 5. Effects of PMA at different extracellular GABA concentrations. 
Cells were incubated in the presence or absence of 100 nM PMA for 
1 h before determining specific [3H]GABA uptake at the indicated 
GABA concentrations. 
tween 1 and = 50/zM, i.e. in a concentration range that is close 
to the KD values of both GABAA receptor binding [20] and 
GATl-mediated transport. Thus, PKC-induced changes of 
GAT1 activity could contribute to the control of synaptic effi- 
cacy in GABAergic systems. 
Regulation of recombinant GAT1 function by PKC phos- 
phorylation has been previously analysed by expressing GAT1 
in Xenopus oocytes. However, the results obtained were contra- 
dictory, since one study reported a PMA-induced GAT1 
downregulation resulting from a decrease of transporter affin- 
the other found enhanced [ H]GABA transport ity [9], whereas 3 
caused by an increase in Vma x value [10]. PKC is known to 
comprise a multigene family that encodes several distinct 
isoforms [21]. Upon activation by phorbol esters, these isoen- 
zymes are specifically translocated to particular subcellular 
structures. This suggests that PKC substrate specificity in vivo 
is critically dependent on the respective cellular localization of 
distinct isoenzymes [22]. In addition, it has been shown that 
closely related isoforms of PKC can cause reciprocal effects 
upon activation by phorbol esters [23]. This may explain how 
different forms of application of phorbol esters (bath applica- 
tion and slow diffusion versus direct cytosolic injection) could 
activate different PKC isoforms, which in turn produce oppo- 
site effects. The observation that removal of all consensus PKC 
sites did not affect the modulation of GAT1 by PMA [10] 
implies that PKC modulation i  PMA injected oocytes involves 
an indirect mechanism. In contrast, the data of Osawa et al. [9] 
may reflect direct phosphorylation a d consequently a distinct 
regulatory mechanism. 
Different lines of evidence indicate that the activity of most 
neurotransmitter ransporter proteins is subject o PKC regula- 
tion. Stimulation of PKC has been shown to downregulate 
transporter-mediated neurotransmitter uptake into different 
subcellular f actions and cellular systems, including (i) glycine 
uptake in human placental choriocarcinoma, C6 glioblastoma 
cells and mammalian cells expressing a recombinant glycine 
transporter [7,8,24], (ii) high-affinity GABA uptake in rat cor- 
tical synaptosomes, primary neurons and glial cells from rat 
brain cortex [9,25], (iii) serotonin uptake into human platelets 
[6,26], and (iv) dopamine uptake into COS cells expressing a 
recombinant dopamine transporter [5]. In case of serotonin and 
dopamine uptake, it could be shown that the observed reduc- 
tion in Vmax values did not result from a decreased number of 
transporter molecules on the cell surface, since PMA treatment 
had no effect on the Bmax values of radiolabelled antagonists 
[5,6,26]. Currently, it is not known wether a similar PKC-driven 
mechanism causes the downregulation of GABA transporter 
activity reported here. 
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